Solasia Pharma K.K. provided consolidated financial guidance for the fiscal year ending December 31, 2022. For the year, the company expects consolidated revenue of ¥2,300 million ~ ¥3,800 million, operating loss of ¥1,100 million ~ operating profit of ¥150 million, net loss attributable to owners of parent of ¥1,200 million ~ net profit attributable to owners of parent of ¥50 million, basic loss per share of ¥8.99 ~ basic earnings per share of ¥0.37.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29 JPY | -3.33% | +7.41% | -35.56% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.56% | 3.69Cr | |
-1.64% | 9.03TCr | |
-1.97% | 3.95TCr | |
-15.47% | 3.17TCr | |
+61.28% | 2.64TCr | |
-22.81% | 1.43TCr | |
-8.82% | 1.29TCr | |
-11.77% | 1.18TCr | |
-45.97% | 1.1TCr | |
+3.30% | 884.67Cr |
- Stock Market
- Equities
- 4597 Stock
- News Solasia Pharma K.K.
- Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022